Risk factors associated with alloimmunization in patients with SCD
| Clinical variables . | Logistic regression analysis∗ . | Multivariate logistic regression analysis using transfusion load . | Multivariate logistic regression analysis using transfusion frequency . | |||
|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) . | P value . | Adjusted OR (95% CI) . | P value . | Adjusted OR (95% CI) . | P value . | |
| All patients | ||||||
| Age at first transfusion (y) | 0.96 (0.90, 1.03) | .31 | — | — | — | — |
| Sex, male vs female | 0.90 (0.48, 1.69) | .75 | — | — | — | — |
| Hb genotype, SS/Sβ0 thalassemia vs Others† | 12.14 (1.64, 89.86) | .015 | 11.22 (1.51, 83.38) | .018 | 5.84 (0.76, 45.67) | .089 |
| Transfusion load (units)‡ | 1.02 (1.01, 1.04) | .007 | 1.02 (1.003, 1.04) | .020 | — | — |
| Transfusion frequency, Chronic vs Episodic | 17.64 (8.19, 38.00) | < .001 | — | — | 14.19 (6.54, 30.80) | < .0001 |
| Patients who received episodic transfusion | ||||||
| HU yes/no | 6.52 (0.85, 49.77) | .071 | — | — | — | — |
| HU therapy duration | 1.13 (0.997, 1.28) | .056 | — | — | — | — |
| HU MTD (mg/kg per d) | 1.06 (0.96, 1.16) | .242 | — | — | — | — |
| Clinical variables . | Logistic regression analysis∗ . | Multivariate logistic regression analysis using transfusion load . | Multivariate logistic regression analysis using transfusion frequency . | |||
|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) . | P value . | Adjusted OR (95% CI) . | P value . | Adjusted OR (95% CI) . | P value . | |
| All patients | ||||||
| Age at first transfusion (y) | 0.96 (0.90, 1.03) | .31 | — | — | — | — |
| Sex, male vs female | 0.90 (0.48, 1.69) | .75 | — | — | — | — |
| Hb genotype, SS/Sβ0 thalassemia vs Others† | 12.14 (1.64, 89.86) | .015 | 11.22 (1.51, 83.38) | .018 | 5.84 (0.76, 45.67) | .089 |
| Transfusion load (units)‡ | 1.02 (1.01, 1.04) | .007 | 1.02 (1.003, 1.04) | .020 | — | — |
| Transfusion frequency, Chronic vs Episodic | 17.64 (8.19, 38.00) | < .001 | — | — | 14.19 (6.54, 30.80) | < .0001 |
| Patients who received episodic transfusion | ||||||
| HU yes/no | 6.52 (0.85, 49.77) | .071 | — | — | — | — |
| HU therapy duration | 1.13 (0.997, 1.28) | .056 | — | — | — | — |
| HU MTD (mg/kg per d) | 1.06 (0.96, 1.16) | .242 | — | — | — | — |
Indicated in bold, P < 0.05 is considered significant.
Adjusted for time on study, which is from patients receiving the first RBC transfusion at our center to the first newly identified antibody for patients who were alloimmunized, and to 31 December 2017 or one day before patients turning 19 years old (whichever came first) for patients who were not alloimmunized.
Others include all non-HbSS/Sβ0–thalassemia genotypes.
OR was based on a 5-unit increase.